| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Josef Schoell last filed a Form 4 in July 2017, as Chief Financial Officer at TVRD. Josef Schoell's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 50,000 shares of TVRD. The TVRD filings lean toward selling, a net 12,000 shares.
Josef Schoell has 7 Form 4 filings on record from February 2015 to July 2017, all as Chief Financial Officer at Tvardi Therapeutics (TVRD), 2015–2017.
The 8 reported transactions were 3 option exercises, 3 option or other derivative awards, 1 open-market purchase and 1 open-market sale.
Counted by filing, the open-market trades come to 1 purchase worth about $66K and 1 sale worth about $164K.
The only open-market purchase was 3,000 shares of TVRD at an average $22.10 on August 18, 2015, about $66K.
The only open-market sale was 15,000 shares of TVRD at an average $10.96 on February 17, 2015, about $164K.
Shares as reported in the last Form 4 for each company; the most recent is from July 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.